Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report
Open Access
- 28 April 2009
- journal article
- case report
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 2 (1), 19
- https://doi.org/10.1186/1756-8722-2-19
Abstract
Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in association with POEMS syndrome and can progress to Kaposi's sarcoma or malignant lymphoma. The disease runs a more aggressive course and a poor prognosis. Optimal therapies have not been well established up to now. We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission. To our knowledge, this is the first report on MCD in the setting of multiple myeloma with good response to bortezomib.Keywords
This publication has 21 references indexed in Scilit:
- Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman diseaseBlood, 2007
- Prospective Study of Rituximab in Chemotherapy-Dependent Human Immunodeficiency Virus–Associated Multicentric Castleman's Disease: ANRS 117 CastlemaB TrialJournal of Clinical Oncology, 2007
- Proteasome inhibition in multiple myelomaEuropean Journal Of Cancer, 2006
- Long‐term remission in HIV‐negative patients with multicentric Castleman's disease using rituximabEuropean Journal of Haematology, 2005
- Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman diseaseBlood, 2005
- Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatmentBlood, 2004
- Rituximab therapy for HIV-associated Castleman diseaseBlood, 2003
- Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomideAmerican Journal of Hematology, 2003
- Successful Treatment of Human Immunodeficiency Virus-Related Castleman's Disease with Interferon-Clinical Infectious Diseases, 2000
- Retinoic acid for treatment of multicentric Castleman's diseaseThe Lancet, 1999